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BACKGROUND
There is considerable variation in disease behavior among patients infected with 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that 
causes coronavirus disease 2019 (Covid-19). Genomewide association analysis may 
allow for the identification of potential genetic factors involved in the development 
of Covid-19.
METHODS
We conducted a genomewide association study involving 1980 patients with 
Covid-19 and severe disease (defined as respiratory failure) at seven hospitals in 
the Italian and Spanish epicenters of the SARS-CoV-2 pandemic in Europe. After 
quality control and the exclusion of population outliers, 835 patients and 1255 
control participants from Italy and 775 patients and 950 control participants from 
Spain were included in the final analysis. In total, we analyzed 8,582,968 single-
nucleotide polymorphisms and conducted a meta-analysis of the two case–control 
panels.
RESULTS
We detected cross-replicating associations with rs11385942 at locus 3p21.31 and 
with rs657152 at locus 9q34.2, which were significant at the genomewide level 
(P<5×10−8) in the meta-analysis of the two case–control panels (odds ratio, 1.77; 
95% confidence interval [CI], 1.48 to 2.11; P = 1.15×10−10; and odds ratio, 1.32; 95% 
CI, 1.20 to 1.47; P = 4.95×10−8, respectively). At locus 3p21.31, the association signal 
spanned the genes SLC6A20, LZTFL1, CCR9, FYCO1, CXCR6 and XCR1. The association 
signal at locus 9q34.2 coincided with the ABO blood group locus; in this cohort, a 
blood-group–specific analysis showed a higher risk in blood group A than in other 
blood groups (odds ratio, 1.45; 95% CI, 1.20 to 1.75; P = 1.48×10−4) and a protective 
effect in blood group O as compared with other blood groups (odds ratio, 0.65; 
95% CI, 0.53 to 0.79; P = 1.06×10−5).
CONCLUSIONS
We identified a 3p21.31 gene cluster as a genetic susceptibility locus in patients 
with Covid-19 with respiratory failure and confirmed a potential involvement of the 
ABO blood-group system. (Funded by Stein Erik Hagen and others.)
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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was discov-ered in Wuhan, China, in late 2019, and 
coronavirus disease 2019 (Covid-19), the disease 
caused by SARS-CoV-2, rapidly evolved into a 
global pandemic.1 As of June 15, 2020, there 
were more than 8.03 million confirmed cases 
worldwide, with total deaths exceeding 436,900.2 
In Europe, Italy and Spain were severely affected 
early on, with epidemic peaks starting in the 
second half of February 2020 (Fig. 1) and 61,507 
deaths reported by June 15, 2020. Covid-19 has 
varied manifestations,3 with the large majority 
of infected persons having only mild symptoms 
or even no symptoms.4 Mortality rates are driven 
predominantly by the subgroup of patients who 
have severe respiratory failure related to intersti-
tial pneumonia in both lungs and acute respira-
tory distress syndrome.5 Severe Covid-19 with re-
spiratory failure requires early and prolonged 
support by mechanical ventilation.6
The pathogenesis of severe Covid-19 and the 
associated respiratory failure is poorly understood, 
but higher mortality is consistently associated with 
older age and male sex.7,8 Clinical associations 
have also been reported for hypertension, diabe-
tes, and other obesity-related and cardiovascular 
disease traits, but the relative role of clinical risk 
factors in determining the severity of Covid-19 
has not yet been clarified.7-11 Observational data 
on lymphocytic endotheliitis and diffuse micro-
vascular and macrovascular thromboembolic com-
plications suggest that Covid-19 is a systemic 
disease that involves injury to the vascular endo-
thelium but provide little insight into the under-
lying pathogenesis.12-14 At the peak of the epidemic 
in Italy and Spain in early 2020, we performed a 
genomewide association study (GWAS) in an at-
tempt to delineate host genetic factors contribut-
ing to severe Covid-19 with respiratory failure. 
The relatively low disease burden of Covid-19 in 
Norway and Germany allowed for a complemen-
tary team to be set up, whereby genotyping and 
analysis could occur in parallel with the rapid 
recruitment of patients in the heavily affected 
Italian and Spanish epicenters.
Me thods
Study Participants and Recruitment
We recruited 1980 patients with severe Covid-19, 
which was defined as hospitalization with respi-
ratory failure and a confirmed SARS-CoV-2 viral 
RNA polymerase-chain-reaction (PCR) test from 
nasopharyngeal swabs or other relevant biologic 
fluids, cross sectionally, from intensive care units 
and general wards at seven hospitals in four cities 
in the pandemic epicenters in Italy and Spain 
(Table S1A in Supplementary Appendix 1, avail-
able with the full text of this article at NEJM.org). 
The hospitals in Italy were the following: Fon-
dazione IRCCS Cá Granda Ospedale Maggiore 
Policlinico in Milan (597 patients); Humanitas 
Clinical and Research Center, IRCCS, in Milan 
(154 patients); and UNIMIB (Università degli Studi 
di Milano–Bicocca) School of Medicine, San Ge-
rardo Hospital, in Monza (a suburb of Milan) 
(200 patients). The hospitals in Spain were the 
following: Hospital Clínic and IDIBAPS (Insti-
tuto de Investigaciones Biomédicas August Pi i 
Sunyer) in Barcelona (56 patients), Hospital Uni-
versitario Vall d’Hebron in Barcelona (337 pa-
tients), Hospital Universitario Ramón y Cajal in 
Madrid (298 patients), and Donostia University 
Hospital in San Sebastian (338 patients).
Respiratory failure was defined in the simplest 
possible manner in order to ensure feasibility: the 
use of oxygen supplementation or mechanical 
ventilation, with severity graded according to the 
maximum respiratory support received at any 
point during hospitalization (supplemental oxy-
gen therapy only, noninvasive ventilatory support, 
invasive ventilatory support, or extracorporeal 
membrane oxygenation). For severity assessments, 
severity was also dichotomized as no mechani-
cal ventilation or mechanical ventilation. Whole-
blood samples or buffy coats from diagnostic 
venipuncture were obtained for DNA extraction.
For comparison, we included 2381 control 
participants from Italy and Spain (Table S1B in 
Supplementary Appendix 1). We recruited 998 
randomly selected blood donors at Fondazione 
IRCCS Cá Granda Ospedale Maggiore Policlinico, 
Milan, who underwent genotyping for the pur-
pose of the present study. A total of 40 of these 
participants had evidence of the development of 
anti–SARS-CoV-2 antibodies, all of whom had 
mild or no Covid-19 symptoms. We also included 
two control panels with genotype data derived 
from previous studies and from persons with 
unknown SARS-CoV-2 infection status using the 
same genotyping array. The panels included 
396 healthy volunteers, blood donors, and outpa-
tients of gastroenterology departments in Italy15 
and 987 healthy blood donors in San Sebastian, 
Spain.
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Ethics Committee Approval
The project protocol involved the rapid recruitment 
of patient-participants and no additional project-
related procedures (we primarily used material 
from clinically indicated venipunctures) and af-
forded anonymity, owing to the minimal data set 
collected. Differences in recruitment and consent 
procedures among the centers arose because 
some centers integrated the project into larger 
Covid-19 biobanking efforts, whereas other cen-
ters did not, and because there were differences 
in how local ethics committees provided guidance 
on the handling of anonymization or deidentifica-
tion of data as well as consent procedures. Writ-
ten informed consent was obtained, sometimes 
in a delayed fashion, from the study patients at 
each center when possible. In some instances, 
informed consent was provided verbally or by the 
next of kin, depending on local ethics committee 
regulations and special policies issued for Covid-19 
research. For some severely ill patients, an exemp-
tion from informed consent was obtained from 
a local ethics committee or according to local 
regulations in order to allow the use of com-
pletely anonymized surplus material from diag-
nostic venipuncture.
The following approvals of the project were 
obtained from the relevant ethics committees: 
Germany: Kiel (reference number, D464/20); Italy: 
Fondazione IRCCS Cá Granda Ospedale Maggiore 
Policlinico (reference numbers, 342_2020 for pa-
tients and 334-2020 for control participants), 
Humanitas Clinical and Research Center, IRCCS 
(reference number, 316/20), the University of Mi-
lano–Bicocca School of Medicine, San Gerardo 
Hospital, Monza (the ethics committee of the 
National Institute of Infectious Diseases Lazzarro 
Spallanzani reference number, 84/2020); Norway: 
Regional Committee for Medical and Health Re-
search Ethics in South-Eastern Norway (reference 
number, 132550); Spain: Hospital Clínic, Barce-
lona (reference number, HCB/2020/0405), Hospital 
Universitario Vall d’Hebron, Barcelona (reference 
number, PR[AG]244/2020), Hospital Universitario 
Ramón y Cajal, Madrid (reference number, 093/20) 
and Donostia University Hospital, San Sebastian 
(reference number, PI2020064).
Sample Processing, Genotyping, and Imputation
We performed DNA extraction using a Chemagic 
360 (PerkinElmer) with the use of the low-volume 
kit CMG-1491 and the buffy-coat kit CMG-714 
(Chemagen), respectively. For genotyping, we used 
the Global Screening Array (GSA), version 2.0 
(Illumina), which contains 712,189 variants be-
fore quality control. Details on genotyping and 
quality-control procedures are provided in the 
Supplementary Methods section in Supplemen-
tary Appendix 1. To maximize genetic coverage, 
we performed single-nucleotide polymorphism 
(SNP) imputation on genome build GRCh38 us-
ing the Michigan Imputation Server and 194,512 
haplotypes generated by the Trans-Omics for Preci-
sion Medicine (TOPMed) program (freeze 5).16
After the exclusion of samples during quality 
control (the majority of which were due to popu-
lation outliers; see the Supplementary Methods 
section and Table S1B and S1C), the final case–
control data sets comprised 835 patients and 
1255 control participants from Italy and 775 
patients and 950 control participants from 
Spain. A total of 8,965,091 SNPs were included 
in the Italian cohort and 9,140,716 SNPs in the 
Spanish cohort.
Statistical Analysis
To take imputation uncertainty into account, we 
tested for phenotypic associations with allele dos-
age data separately for both the Italian and 
Spanish case–control panels with the use of the 
PLINK logistic-regression framework for dosage 
data (PLINK, version 1.9).17 We carried out two 
genomewide tests of association that included 
covariates from principal-component analyses, 
with adjustments to control for potential popu-
lation stratification (main analysis) and poten-
tial population stratification and age and sex 
bias (analysis corrected for age and sex). A fixed-
effects meta-analysis was conducted with the use 
of the meta-analysis tool METAL18 on 8,582,968 
variants that were common to both the Italian 
and Spanish data sets with the use of effect-size 
estimates and their standard errors from the study-
specific association analyses.
For the genomewide meta-analysis, we used 
the commonly accepted threshold of 5×10−8 for 
joint P values to determine statistical significance. 
Bayesian fine-mapping analysis was performed 
for loci reaching genomewide significance (see the 
Supplementary Methods section). Genomewide 
summary statistics of our analyses are publicly 
available through our web browser (www . c19 
- genetics . eu) and have been submitted to the 
European Bioinformatics Institute (www . ebi . ac 
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. uk/ gwas; accession numbers, GCST90000255 and 
GCST90000256).
On the basis of the results from the TOPMed 
genotype imputation, we selected three ABO SNPs 
(rs8176747, rs41302905, and rs8176719)19,20 to in-
fer the ABO blood type and calculated odds ratios 
according to blood type (A vs. B, AB, or O; B vs. 
A, AB, or O; AB vs. A, B, or O; and O vs. A, AB, 
or B) (see the Supplementary Methods). To assess 
in detail the HLA complex at locus 6p21, we per-
formed sequencing-based HLA typing of seven 
classical HLA loci (HLA-A, -C, -B, -DRB1, -DQA1, 
-DQB1, and -DPB1) in a subgroup of 835 patients 
and 891 control participants from Italy and 773 
patients from Spain (see the Supplementary Meth-
ods). We also assessed allelic distribution accord-
ing to no mechanical ventilation (supplemental 
oxygen only) as compared with mechanical venti-
lation of any type. A similar assessment was 
made for lead SNPs rs11385942 and rs657152 at 
loci 3p21.31 and 9q34.2, respectively.
R esult s
Patients, Genotyping, and Quality Control
The milestones of the study in the context of the 
peak outbreaks in Italy and Spain are shown in 
Figure 1. Data on the age, sex, maximum respira-
tory support at any point during hospitalization, 
and relevant coexisting conditions (type 2 diabe-
tes, hypertension, and coronary heart disease) in 
the patients who were included in the final analy-
sis are shown in Table 1 and in Table S2 in Supple-
mentary Appendix 1. Because we used the same 
genotyping platform (GSA) to obtain both data 
sets, we were able to perform a uniform quality 
control of the merged Italian and Spanish SNP 
data sets, thus reducing technical confounders to 
a minimum. A quantile–quantile (Q-Q) plot of the 
two meta-analyses (the main analysis and the 
analysis corrected for age and sex) showed sig-
nificant associations in the tail of the distribution 
with minimal genomic inflation (λGC = 1.015 for 
main analysis and λGC = 1.006 for analysis correct-
ed for age and sex) (Fig. S2 in Supplementary Ap-
pendix 1). We also carried out separate association 
analyses for the Italian and Spanish data sets (see 
the Supplementary Methods section and Fig. S3).
Genomewide Association Analysis
We found two loci to be associated with Covid-19–
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nificance (P<5×10−8) in the main meta-analysis: 
the rs11385942 insertion–deletion GA or G vari-
ant at locus 3p21.31 (odds ratio for the GA allele, 
1.77; 95% confidence interval [CI], 1.48 to 2.11; 
P = 1.15×10−10) and the rs657152 A or C SNP at 
locus 9q34.2 (odds ratio for the A allele, 1.32; 
95% CI, 1.20 to 1.47; P = 4.95×10−8) (Fig. 2 and 
Table 2 and Supplementary Appendix 2, available 
at NEJM.org). Both loci showed nominally sig-
nificant association in both the Spanish and 
Italian subanalyses (Table 2). The meta-analysis 
association results for recessive and heterozygous 
genetic models for the two meta-analyses (main 
analysis and the analysis corrected for age and 
sex) are provided in Supplementary Appendix 3, 
available at NEJM.org. The imputation quality of 
the associated markers was good (Table 2 and 
Supplementary Appendix 2), and manual inspec-
tion of genotype cluster plots of genotyped SNPs 
in these regions showed distinct genotype clouds 
for homozygous and heterozygous calls (Fig. S4 
in Supplementary Appendix 1). Furthermore, the 
analyses that were corrected for age and sex cor-
roborated the observations at both rs11385942 
(meta-analysis odds ratio, 2.11; 95% CI, 1.70 to 
2.61; P = 9.46×10−12) and rs657152 (meta-analysis 
odds ratio, 1.39; 95% CI, 1.22 to 1.59; P = 5.35×10−7) 
(Table 2 and Fig. S5 in Supplementary Appendix 1).
The allele frequencies in Spanish and Italian 
control data sets from previously published stud-
ies21-27 are consistent with those we report here 
(Supplementary Appendix 2). A further 24 differ-
ent genomic loci showed suggestive evidence 
(P<1×10−5) for association with Covid-19–induced 
respiratory failure in the main analysis (Supple-
mentary Appendix 4, available at NEJM.org, and 
Fig. S6 in Supplementary Appendix 1). Associa-
tion signals at loci 3p21.31 and 9q34.2 were fine-
mapped to 22 and 38 variants, respectively, with 
greater than 95% certainty (Fig. 3A and 3B and 
Supplementary Appendix 5, available at NEJM.org).
 Chromosome 3p21.31
The association signal at locus 3p21.31 com-
prised six genes (SLC6A20, LZTFL1, CCR9, FYCO1, 
CXCR6, and XCR1) (Fig. 3A). The risk allele GA of 
rs11385942 is associated with reduced expression 
of CXCR6 and increased expression of SLC6A20, 
and LZTFL1 is strongly expressed in human lung 
cells (Fig. S7 and Supplementary Appendix 6, 
available at NEJM.org). We found that the fre-
quency of the risk allele of the lead variant at 
3p21.31 (rs11385942) was higher among patients 
who received mechanical ventilation than among 
those who received oxygen supplementation only 
in both the main meta-analysis (odds ratio, 1.70; 
95% CI, 1.27 to 2.26; P = 3.30×10−4) and the me-
ta-analysis corrected for age and sex (odds ratio, 
1.56; 95% CI, 1.17 to 2.01; P = 0.003) (Supple-
mentary Appendix 7, available at NEJM.org). Fur-
thermore, the 19 patients who were homozygous 
for the rs11385942 risk allele were younger than 
Figure 2. GWAS Summary (Manhattan) Plot of the Meta-analysis Association Statistics Highlighting Two Susceptibility Loci with Genomewide 
Significance for Severe Covid-19 with Respiratory Failure.
Shown is a Manhattan plot of the association statistics from the main meta-analysis (controlled for potential population stratification). 
The red dashed line indicates the genomewide significance threshold of a P value less than 5×10−8. Figure S6 in Supplementary Appen-
dix 1 shows Manhattan plots that include hits passing a suggestive significance threshold of a P value less than 1×10−5 (total of 24 addi-
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1591 patients who were heterozygous or homo-
zygous for the nonrisk allele (median age, 59 years 
[interquartile range, 49 to 68] vs. 66 years [inter-
quartile range, 56 to 75]; P = 0.005). Available vari-
ant database entries suggest that the frequency of 
this risk allele varies among populations world-
wide (Fig. S8 in Supplementary Appendix 1).
ABO Locus
At locus 9q34.2 the association signal coincided 
with the ABO blood group locus (Fig. 3B and Fig. 
S9 in Supplementary Appendix 1). Accordingly, 
the distribution of ABO blood groups (predicted 
from combinations of genotypes of three different 
SNPs) was skewed among patients with Covid-19 
who had respiratory failure, as compared with the 
distribution among control participants. In the 
meta-analysis corrected for age and sex, we found 
a higher risk among persons with blood group A 
than among patients with other blood groups 
(odds ratio, 1.45; 95% CI, 1.20 to 1.75; P = 1.48×10−4) 
and a protective effect for blood group O as com-
pared with the other blood groups (odds ratio, 
0.65; 95% CI, 0.53 to 0.79; P = 1.06×10−5). Details 
are provided in Supplementary Appendix 8, avail-
able at NEJM.org. Both associations and effect 
directions were consistent in the separate Span-
ish and Italian case–control analyses. We found 
no significant difference in blood-group distri-
bution between patients receiving supplemental 
oxygen only and those receiving mechanical ven-
tilation of any kind. The ABO blood-group fre-
quency distributions in public registries are pro-
vided for comparison in Supplementary Appendix 
8, along with details of the results presented 
here, and corroborate our observations.
HLA Analysis
Given its important role in several viral infec-
tions, we scrutinized the extended HLA region 
(chromosome 6, 25 through 34 Mb). There were 
no SNP association signals at the HLA complex 
that met even the significance threshold of sug-
gestive association: P<1×10−5 (Fig. S10 in Supple-
mentary Appendix 1). Dedicated analysis of the 
classical HLA loci showed no significant allele 
associations with either Covid-19 or disease se-
verity (oxygen supplementation only or mechan-
ical ventilation of any kind), and further analysis 
of heterozygote and divergent allele advantage or 
predicted number of HLA-bound SARS-CoV-2 pep-
tides did not show significant associations with 
Covid-19 in this data set (see the HLA Analyses 
section in Supplementary Appendix 1 and Sup-
plementary Appendix 9, available at NEJM.org).
Discussion
Using a pragmatic approach with simplified in-
clusion criteria and a complementary team of clini-
cians at the European Covid-19 epicenters in Italy 
and Spain and scientists in the less-burdened 
countries of Germany and Norway, we performed 
a GWAS that included de novo genotyping for 
Covid-19 with respiratory failure in approxi-
mately 2 months. We detected a novel susceptibil-
ity locus at a chromosome 3p21.31 gene cluster 
and confirmed a potential involvement of the 
ABO blood-group system in Covid-19.
On chromosome 3p21.31, the peak association 
signal covered a cluster of six genes (SLC6A20, 
LZTFL1, CCR9, FYCO1, CXCR6, and XCR1), several 
of which have functions that are potentially rel-
evant to Covid-19. A causative gene cannot be reli-
ably implicated by the present data. One candidate 
is SLC6A20, which encodes the sodium–imino 
acid (proline) transporter 1 (SIT1) and which func-
tionally interacts with angiotensin-converting en-
zyme 2, the SARS-CoV-2 cell-surface receptor.28,29 
However, the locus also contains genes encod-
ing chemokine receptors, including the CC motif 
chemokine receptor 9 (CCR9) and the C-X-C 
motif chemokine receptor 6 (CXCR6), the latter 
of which regulates the specific location of lung-
resident memory CD8 T cells throughout the 
sustained immune response to airway patho-
gens, including influenza viruses.30 Flanking 
genes (e.g., CCR1 and CCR2) also have relevant 
functions,31 and further studies will be needed 
to delineate the functional consequences of de-
tected associations.
The preliminary results from the Covid-19 
Host Genetics Consortium32 include suggestive 
associations within the same locus at chromo-
some 3p21.31, which lend considerable support 
to our findings (Fig. S11 in Supplementary Ap-
pendix 1). The consortium analysis also used 
population-based controls, but the patients in-
cluded persons with mild Covid-19 and those 
with severe Covid-19. The parallel findings nev-
ertheless underscore an important point about 
the ascertainment of patients and controls in 
genetic studies of Covid-19. Because the majority 
of patients with SARS-CoV-2 infection are asymp-
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tomatic, any sample involving patients with a 
positive nasopharyngeal RNA test is likely to 
hold a bias toward some degree of symptomatic 
burden. Two of the identifiers for inclusion in 
the current study were a positive result for the 
presence of SARS-CoV-2 according to PCR test-
ing and receipt of respiratory support (an ex-
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reasonable to conclude that the chromosome 
3p21.31 locus is involved in Covid-19 susceptibil-
ity per se, with a possible enrichment in patients 
with severe disease. This latter interpretation is 
supported by the significantly higher frequency 
of the risk allele among patients who received 
mechanical ventilation than among those who 
received supplemental oxygen only as well as by 
the finding of younger age among patients who 
were homozygous for the risk allele than among 
patients who were heterozygous or homozygous 
for the nonrisk allele.
Nongenetic studies that were reported as pre-
prints33,34 have previously implicated the involve-
ment of ABO blood groups in Covid-19 suscepti-
bility, and ABO blood groups have also been 
implicated in susceptibility to SARS-CoV-1 infec-
tion.35 Our genetic data confirm that blood 
group O is associated with a risk of acquiring 
Covid-19 that was lower than that in non-O blood 
groups, whereas blood group A was associated 
with a higher risk than non-A blood groups.33,34 
The biologic mechanisms undergirding these 
findings may have to do with the ABO group per 
se (e.g., with the development of neutralizing 
antibodies against protein-linked N-glycans)36 or 
with other biologic effects of the identified vari-
ant,37-39 including the stabilization of von Wille-
brand factor.40,41 The ABO locus holds consider-
able risk for population stratification,42 which is 
increased by the inclusion of randomly selected 
blood donors in the current study (for which there 
is an inherent risk of blood group O enrichment). 
Alignment of the allele frequencies at the ABO 
locus in our control population with those in 
several non–blood-donor control populations 
would suggest that this is not a major bias, and 
at least one study34 that tested for association 
with blood type used disease controls with no 
affiliation to blood donors.
The pragmatic aspects leading to the feasibil-
ity of this massive undertaking in a very short 
period of time during the extreme clinical cir-
cumstances of the pandemic imposed limita-
tions that will be important to explore in follow-
up studies. For example, to enable the recruitment 
of study participants, a bare minimum of clinical 
metadata was requested. For this reason, exten-
sive genotype–phenotype elaboration of current 
findings could not be conducted, and adjust-
ments for all potential sources of bias (e.g., un-
derlying cardiovascular and metabolic factors 
relevant to Covid-19) could not be performed. 
Furthermore, we have limited information about 
the SARS-CoV-2 infection status in the control 
participants; this concern is mitigated by the fact 
that the presence of susceptible persons in the 
control group would only bias the tests toward 
the null. In addition, few restrictions were im-
posed during inclusion, which led to genotyped 
samples having to be excluded owing to differ-
ing ethnic groups (population outliers). Further 
exploration of current findings, both as to their 
usefulness in clinical risk profiling of patients 
with Covid-19 and toward a mechanistic under-
standing of the underlying pathophysiology, is 
warranted.
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